MedTrace Logo

Assess Efficacy in Subjects With Traumatic Spinal Cord Injury

NCT00667966 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2015-05-06

No results posted yet for this study

Summary

Assess efficacy of Vardenafil in patients with traumatic spinal cord injury

Conditions

Interventions

DRUG

Vardenafil (Levitra, BAY 38-9456), 10 mg

10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.

DRUG

Placebo

10/20 mg placebo in sequence in respective arm

DRUG

Vardenafil (Levitra, BAY 38-9456), 20 mg

20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2007-02-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00667966 on ClinicalTrials.gov